Sign in

    Brian Charles • R.W. Pressprich & Co.

    Brian Charles is the Managing Director and Head of Research at R.W. Pressprich & Co., specializing in fixed income and equity analysis with deep expertise in the financial services industry and special situations among high-yield and investment-grade corporate issuers. He covers specific companies including CIT Group, distressed banks, airline lessors, telecommunications firms, and issuers across metals, mining, chemicals, and healthcare, and has published over 280 research reports during his tenure. Having joined R.W. Pressprich in December 2008 after previous roles at ASB Capital Management, Friedman Billings Ramsey, and Banc One Capital Markets, Charles has developed corporate sector strategies for portfolios up to $400 million and built a reputation for insightful sector performance, though published rankings or return statistics are not publicly available. He holds an MBA in Finance from Georgetown University, a BA from Colorado College, and is a CFA charterholder, reflecting his strong professional and analytical credentials.

    Brian Charles's questions to Innovate Corp (VATE) leadership

    Brian Charles's questions to Innovate Corp (VATE) leadership • Q4 2024

    Question

    Brian Charles of R.W. Pressprich & Co. inquired about the progress of monetizing MediBeacon following its FDA approval, asking about the depth of discussions with Jefferies, the relevance of its prior $400 million valuation, and the potential impact of tariffs on both MediBeacon and the DBM Global backlog.

    Answer

    CFO Michael Sena explained that the process to monetize MediBeacon has been underway since late 2023 and that they are in active discussions with potential partners. Sena noted the prior $400 million valuation was from a 2019 commitment and the outcome of the current process remains to be seen. He also stated that the company does not anticipate a material impact from tariffs on either MediBeacon at this early stage or on DBM Global's backlog, as DBM typically passes on steel price risk.

    Ask Fintool Equity Research AI